Clinical Trials Logo

Clinical Trial Summary

This study is a pre-test, post-test single group design with follow-up at month three. Twenty-four individuals total will participate in this study with 6 participants in each of 4 cohorts. Participants and their parents will complete pre-test measures including both paper and pencil measures and a video-recording to assess the participant's social interaction skills and fluency. These adolescents will participate in both group therapy and peer generalization sessions once a week over the course of twelve weeks. Upon completion of the intervention, participants and parents will complete paper and pencil and video post-test measures. Participants will be encouraged to participate in one follow-up session where the paper and pencil and video measures will be completed again.


Clinical Trial Description

After consent , has been obtained, parents will complete the Autism Disorders Interview-Revised (ADI-R; Rutter & LeCourteur, 1995) to determine eligibility and the Checklist for Autism Spectrum Disorder (Mayes & Calhoun, 1999), the Social Responsiveness Scale (SRS; Constantino, 2002), and the Strengths and Difficulties Questionnaire (SDQ; Goodman, 1997) at the initial appointment with the study coordinator.

After assent has been obtained, adolescents will complete the Kaufman Brief Intelligence Test, Second Edition (KBIT-2; Kaufman & Kaufman, 1990) to determine eligibility and the Checklist for Autism Spectrum Disorder (Mayes & Calhoun, 1999), the Strengths and Difficulties Questionnaire (SDQ; Goodman, 1997) and the Loneliness Scale (Asher & Wheeler, 1985). Adolescents will also complete a standardized joint attention assessment.

After the completion of the eligibility and pre-test interventions there will be a wash of participants who do not meet eligibility requirements.

One week before the start of the program, participants will attend an introduction session to the program. At this time, participants will be filmed in a brief interaction with a typically developing peer that will be used as a baseline indicator of their social fluency.

Participants will attend the social skills intervention program once a week for twelve weeks. Each week there will be approximately 90 minutes of group therapy which will be conducted like a seminar class: the principal investigator will teach and review social interaction skills and nuances, participants will be encouraged to take an active role in the class.

During the twelve week intervention there will be three review/fluency building sessions: week four, week eight, and week twelve. The group therapy sessions for these review weeks will simply review the material that was covered during the prior three weeks. Participants will then practice what they have learned by having a conversation with a peer that will be taped.

Following the group therapy session each week, participants will join six typically developing peers in a 90 minute introductory photography class taught by one of the study's co-investigators. The photography class will give the participants the opportunity to practice the skills learned in group therapy with their peer group.

Participants will once again complete a battery of clinical and self-report outcome measures which will serve as the post-test measurements for the study. They will be filmed in a brief interaction with a typically developing peer which will be coded to obtain post-test social interaction skills and fluency scores. These evaluations will occur at completion of social skills program, and at three month follow-up. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01031823
Study type Interventional
Source Milton S. Hershey Medical Center
Contact
Status Completed
Phase N/A
Start date November 2009
Completion date July 10, 2013

See also
  Status Clinical Trial Phase
Completed NCT01592747 - Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine Phase 2
Withdrawn NCT00376194 - Mercury Chelation to Treat Autism Phase 2
Terminated NCT01592773 - Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Phase 2
Enrolling by invitation NCT01078844 - Memantine in Adult Autism Spectrum Disorder N/A
Completed NCT00844753 - Atomoxetine, Placebo and Parent Management Training in Autism Phase 4
Completed NCT00352196 - Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study Phase 4
Completed NCT01631851 - Cognitive-Behavioral Therapy for Irritability in Adolescents With High Functioning Autism Spectrum Disorder N/A
Completed NCT01086475 - D-Cycloserine and Social Skills Training in Autism Spectrum Disorders Phase 3
Active, not recruiting NCT02199925 - An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum Phase 4
Completed NCT01592786 - An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Phase 2
Completed NCT01808066 - GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs N/A
Completed NCT00198055 - A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder. Phase 2
Active, not recruiting NCT01031407 - Cognitive Neuroscience of Autism Spectrum Disorders
Completed NCT00308074 - An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders Phase 2
Completed NCT00808782 - The Use of rTMS to Improve Theory of Mind Among Adults With Autism and Asperger's Disorder N/A